Press release
WEHEALTH BY SERVIER AND CUREMATCH ANNOUNCE PARTNERSHIP TO DELIVER A DECISION-SUPPORT DIGITAL PLATFORM FOR ONCOLOGISTS WORLDWIDE
CureMatch and WeHealth by Server - A new partnership to develop a digital support platform fro oncologists around the world.
Today, oncologists face the daunting task of understanding thousands of genomic abnormalities and hundreds of drugs in order to select treatment options for their cancer patients. Powerful new technologies like next generation sequencing have uncovered enormous heterogeneity amongst cancer patients, which tremendously complicates the decision-making process. “Each cancer is like a snowflake—complex and unique,” says Dr. Razelle Kurzrock, one of the world’s leading precision medicine oncologists and CureMatch Founder. “Their genetic profile is unique, their tumors are unique, and their treatment should account for these differences.”
“The vision of WeHealth is to offer a precision medicine approach where the patient is at the center of an individualized diagnosis and treatment. Our collaboration with CureMatch opens a large spectrum of potential benefits for the patients and for oncologists through a better disease management,” says Dr. David Guez, Director General of WeHealth by Servier.
The WeHealth by Servier/CureMatch partnership will bring the best of both worlds together in the fight against cancer. “As a small, innovative company at the leading edge of precision medicine, we know we have something special to offer, but we don’t have the scale or infrastructure of a large company”, says Bob Manning, CEO of CureMatch. “Our partnership with WeHealth will provide corporate size and strength to reach oncologists around the world so much faster than we ever could on our own. The power of the partnership goes beyond the power of WeHealth as it encompasses Servier’s sales and marketing expertise, and provides co-development efforts around additional software development and clinical trial programs.”
About WeHealth by Servier
WeHealth by Servier, launched in November 2016 and aiming to improve the daily life of patients and health professionals’ alike using digital, is the e-Health business unit of the Servier Group. WeHealth by Servier proposes innovative digital and connected solutions as well as services by making the most of collected data, to ensure better individual monitoring of the patient and to better prevent and predict the evolution of the disease mainly in cardiovascular, neurology, diabetes and oncology fields. In an open innovative approach, WeHealth by Servier identifies the most promising start-ups in e-health, in France and internationally, to co-develop solutions. In this way, WeHealth by Servier contributes to the creation of an ecosystem of partners to facilitate and accelerate the development, industrialization and distribution of innovations and to make them accessible to the greatest number. For further information: www.wehealthbyservier.com
About Servier
Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 149 countries and a turnover of 4.2 billion euros in 2018, Servier employs 22 000 people worldwide. Entirely independent, the Group reinvests 25% of its turnover (excluding generic drugs) in research and development and uses all its profits for development. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neuropsychiatric diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development. More information: www.servier.com
Press Contacts:
Sonia Marques : media@servier.com – Tel. +33 (0)1 55 72 40 21 / + 33 (0) 7 84 28 76 13
Jean-Clément Vergeau : media@servier.com – Tel. +33 (0)1 55 72 46 16 / + 33 (0) 6 79 56 75 96
Karine Bousseau : media@servier.com – Tel. +33 (0)1 55 72 60 37 / + 33 (0) 6 49 92 16 05
About CureMatch
CureMatch™, Inc. is a San Diego-based digital health company focused on personalized medicine and combination therapy in oncology. CureMatch’s Decision Support System guides oncologists in the selection of cancer drugs that are customized for individual patients based on their molecular tumor profile. CureMatch enables oncologists to become experts in personalized medicine by providing them with actionable intelligence towards advanced cancer treatment options. www.curematch.com
Press Contact
Bob Manning, CEO
press@curematch.com
(858) 859-2873
###
CureMatch is a biotech company focused on personalized medicine and combination therapy in oncology. CureMatch’s decision support system guides oncologists in the selection of cancer drugs customized for patients based on active biomarkers.
CureMatch, Inc.
6440 Lusk Blvd, Suite D206
San Diego, CA 92121, USA
Press Contact
Bob Manning, CEO
press@curematch.com
(858) 859-2873
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release WEHEALTH BY SERVIER AND CUREMATCH ANNOUNCE PARTNERSHIP TO DELIVER A DECISION-SUPPORT DIGITAL PLATFORM FOR ONCOLOGISTS WORLDWIDE here
News-ID: 1640949 • Views: …
More Releases for Servier
Isocitrate Dehydrogenase Inhibitors Competitive Landscape Strengthens With Servi …
DelveInsight's report on Isocitrate Dehydrogenase Inhibitors market reveals substantial growth potential through 2034, featuring key players, Servier, Bristol Myers Squibb, Rigel Pharmaceuticals, and Bayer, among others, developing targeted therapies for IDH-mutant cancers including AML, cholangiocarcinoma, and gliomas across 7MM regions.
Isocitrate Dehydrogenase Inhibitors Key Takeaways
*
IDH Inhibitors Market size projection: As per DelveInsight's analysis, the total market size of IDH inhibitors in the 7MM is expected to surge significantly by 2034,…
Ephedrine Market Deep Research Report with Forecast to 2032 | Servier, Merck Sha …
The Ephedrine Market Report is the result of extensive research and analysis conducted by our team of experienced market researchers. It encompasses a wide range of critical factors influencing the Ephedrine Market, including competitive landscape, consumer behavior, and technological advancements. This report serves as a valuable resource for industry players, helping them make informed decisions and stay ahead of the competition in a rapidly evolving market landscape. With its comprehensive…
Indapamide Market is Thriving Global with Servier, Supra Chemicals, Mylan, Cigna …
The Global Indapamide Market Size is Projected to Reach a CAGR of +4% during 2023-2030.
Indapamide is a thiazide-like diuretic that is commonly used to treat hypertension and decompensated heart failure. Perindopril (an ACE inhibitor antihypertensive) is also available in combination compositions.
The Indapamide Market Research Reports 2030 offers an extensive collection of reports on different markets covering crucial details. The report studies the competitive environment of the Indapamide Market based on…
Global Agomelatine Industry Chain Research Report 2021|Servier, Rovi Pharma, Nov …
Complete study of the global Agomelatine market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of the present as well as future scenario of the global Agomelatine industry. Research techniques like PESTLE and Porter's Five Forces analysis have been deployed by the researchers. They have also provided accurate…
Indapamide Market Industry Analysis and Forecast Till 2027| Servier, Cigna, ANI …
Indapamide is a thiazide-like diuretic that is commonly used to treat hypertension and decompensated heart failure. Perindopril (an ACE inhibitor antihypertensive) is also available in combination compositions.
Request Sample Copy of Indapamide Market Report: https://www.infinitybusinessinsights.com/request_sample.php?id=603636
Top Key Players Included in Indapamide Market Report: Servier, Cigna, ANI Pharma, Mylan, Teva, Shandong Yinfeida Pharmaceutical, Taj Pharmaceuticals, Supra Chemicals, Glenmark Pharmaceuticals, Suzhou Lixinpharm, Lisheng Pharma, and Apeloa Kangyu
The global Indapamide market vivaciously used in the…
Global Ephedrine Market 2020 Analysis and Precise Outlook -: Pfizer, Servier, Ro …
The Global Ephedrine Market Research Report 2020-2026 is a valuable source of insightful data for business strategists. It provides the industry overview with growth analysis and historical & futuristic cost, revenue, demand and supply data (as applicable). The research analysts provide an elaborate description of the value chain and its distributor analysis. This Market study provides comprehensive data which enhances the understanding, scope and application of this report.
Top leading Companies…
